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comparative effectiveness and economics information to better inform decision 
making in the evaluation of new health technologies. The impact of comparative 
effectiveness research and economics on formulary decision making will likely have 
more impact in the future. If study data are to be considered valuable in supporting 
health care decision-making, the rigor, transparency, and the customer perspective 
needs to drive the study methods and designs.
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OBJECTIVES: Post-hoc subgroup analyses are still used in clinical trials of medi-
cal technologies to identify patient populations in whom greatest benefits can 
be achieved, despite this being derided as an analytical approach. Indeed, using 
post-hoc analyses, aspirin has been shown to be ineffective in acute myocardial 
infarction patients born under the star signs of Libra and Gemini (ISIS-2, 1988, 
Lancet) and endarterectomy is only efficacious in treating symptomatic steno-
sis patients born on a Monday, Wednesday, or Friday (ECST group, 1998, Lancet). 
This research aimed to determine whether National Institute of Health and Care 
Excellence (NICE) appraisal recommendations could be correlated with full moon 
dates through application of a post-hoc analysis. METHODS: All NICE final appraisal 
determinations were identified up to October 2014 from which the date and deci-
sion was extracted. Full moon dates for Manchester were extracted from www.
timeanddate.com. Statistical comparisons were performed using a Chi-squared 
test. RESULTS: 532 appraisals were identified, 408 (77%) of which were approved 
(defined as ‘recommended’ or ‘optimised’). However, among the 38 recommenda-
tions issued ±1 day of a full moon this recommendation rate significantly rose to 
89% (34/38, p< 0.05). Significantly fewer appraisals also occurred in the 14-day period 
bisected by full moons versus the 14-day period bisected by new moons (183 vs. 359, 
p< 0.0001). CONCLUSIONS: Based on our post-hoc analysis, the NICE committee are 
unduly afraid of werewolves leading them being less productive around the period 
of a full moon. However, if they are pushed to issue a final recommendation close to 
a full moon they will more likely issue a positive recommendation. As werewolves 
are afraid of running water, the feasibility of constructing a moat around the NICE 
headquarters should be explored. Alternatively, regulators and HTA bodies should 
continue to view efficacy claims on the basis of post-hoc sub-group analyses with 
great scepticism.
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OBJECTIVES: To identify the predictors of the nurses undergoing a Compliance 
Monitoring Program (CMP) for substance/drug abuse successfully and assessing the 
effect of these variables on the successful completion of program. METHODS: This 
was a retrospective cross-sectional cohort study using the de-identified data from 
the Florida Intervention Project for Nurses (IPN). Status of CMP program categorized 
as ‘completed’ and ‘Incomplete’ formed the dependent variable. The independent 
variables were characteristics of the nurses - demographic (education, marital sta-
tus), type of treatment employed, years of nursing experience, healthcare institu-
tional setting that employed the nurses, healthcare specialty of nurses, diagnostic 
and statistical manual of mental disorders (DSM-axes), lab results for presence of 
drugs, presence of substance related disorders (dependency, abuse), family history 
of biological, non-biological and mental diseases, lab test results during relapse, if 
aftercare is required at end of program, status of treatment at end of program, type 
of contract, reason for dismissal from program and whether individual treatment 
is required. Imputation procedures using the Markov chain Monte Carlo simulation 
with maximum-likelihood estimation were employed to fill missing data. Statistical 
tests included descriptive analysis including chi-square tests followed by logistic 
regression (p< 0.05). RESULTS: All independent variables except family history of 
mental diseases were found associated with the status of the CMP. The stepwise 
logistic regression yielded only nursing experience in years, type of healthcare insti-
tution, specialty, nursing license and treatment (all p< 0.0001) were found associ-
ated with the completion of the CMP at p< 0.05. CONCLUSIONS: Nursing profession 
characteristics like healthcare setting, specialty and years of experience seemed to 
have a higher association with completion of the CMP for substance abuse.
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OBJECTIVES: Since July 2012, a new therapy may be allocated Breakthrough Therapy 
status if it a) treats a serious and life-threatening condition, and b) preliminary 
evidence suggests substantial clinical improvement over existing therapies based 
on a clinically meaningful endpoint. For such agents, the FDA will expedite their 
development and review. This research aimed to systematically analyse all therapies 
have been approved under this new FDA expedited review pathway. METHODS: All 
publically available FDA documents relating to the approval of therapies under a 
breakthrough status were extracted up to 28th November 2014 and their date, drug 
type, and supportive trial package were extracted. RESULTS: The FDA has approved 
14 therapeutic agents designated as breakthrough therapies (to 1st December 2014), 
7 oncologics, 6 non-oncologics and 1 vaccine. 6/14 also simultaneously received FDA 
accelerated approval. 9 submissions were first approvals whereas 5 were line exten-
sions. 7 of these submissions were based on Phase 3 trial data, 5 on phase 2, and 2 
on phase 1 data. The average review time from submission to approval was 181 days 
(range: 126 – 242 days). There appeared no correlation between review times and 
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OBJECTIVES: The breakthrough therapy pathway provides an expedited Food and 
Drug Administration (FDA) review where preliminary clinical evidence suggests 
potentially substantial clinical improvement for a serious, life-threatening condi-
tion. This has enabled regulatory approval on data packages as early as Phase 1 data 
(ceritinib and pembrolizumab.) We wanted to research the question of whether 
such clinical data would be sufficient for US payer coverage. METHODS: On 5th 
December 2014, publically available benefits documents were extracted from 3 
national (AETNA, Anthem, and United Healthcare [UHC]) and 1 regional (Rocky 
Mountain) insurance companies for the 14 therapies approved by the FDA under 
this pathway. The coverage status, prior authorisation criteria, and price were 
compared. RESULTS: Most of the 14 FDA-approved drugs under the Breakthrough 
Therapy designation were covered by these insurers (AETNA: 10/14, UHC: 10/14, 
Anthem: 9/14, Rocky Mountain: 7/14). Most instances of drugs not covered reflect 
those approved very recently. However, the majority were subject to prior authori-
zations (AETNA: 10/10, Anthem: 9/9, UHC: 5/10, Rocky Mountain: 7/7). These prior 
authorizations sometimes included clinical criteria more stringent than those in the 
FDA label (15/31 similar to FDA label, 9/31 slightly more restrictive, 7/31 much more 
restrictive). The drugs most frequently subject to much greater restrictions than the 
FDA label were Sovaldi and Harvoni. The level of restrictions were not seemingly 
related to the patient cost per treatment which ranged up to $307,000 (Kalydeco) but 
rather seemed correlated with budget impact (very large with Sovaldi and Harvoni, 
indicated for Hepatitis C). CONCLUSIONS: Breakthrough status can result in early 
US payer approval in addition to regulatory approval. Insurers may place additional 
restrictions through prior authorizations but this relates more to the budget impact 
of the drugs than the cost per patient or level of supportive clinical evidence.
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OBJECTIVES: The US is the largest prescription drug market in the world, charac-
terised by high drug prices internationally with traditionally few price controls. 
This sustainability of the largely free-pricing of pharmaceuticals has long been 
questioned against the background of increasing pharmaceutical spend. The recent 
market entrants of innovative Hepatitis C virus (HCV) therapies with potentially 
substantial budgetary implications have driven US public and private payers to 
implement a range of cost-containment mechanisms. This research aims to com-
pare these new changes with European processes and predict how the future 
pricing and reimbursement (P&R) landscape will evolve in the US. METHODS: A 
thematic analysis of P&R changes and activities in the US December 2013-January 
2015 was undertaken, with the outcomes analysed in the context of European P&R 
processes. RESULTS: The range of novel cost-control mechanisms in the US includes 
major pharmacy benefits management organisations (CVS and Express Scripts) 
agreeing exclusivity deals with a particular HCV drug manufacturer, based on the 
most competitively priced. Further, the California Technology Assessment Forum, 
which had only previously evaluated one drug in its 13 year history, has undertaken 
already one review of HCV therapies (with another one ongoing) recommending 
restricting SOVALDI and OLYSIO to the most severe patients based on a cost-utility 
analysis. Further, under Medicaid, nearly half of all states have restricted SOVALDI 
beyond the FDA-approved label. CONCLUSIONS: Cost-control mechanisms in the US 
have started to reshape the P&R landscape with European-style price competition, 
restricting drugs to subpopulations beyond the label, and cost-effectiveness analy-
ses utilisation now starting to take hold. As pharmaceutical spend continues to grow, 
such cost-management tools will become further embedded in a wider variety of 
US payers. With variable usage of distinct cost-containment tools by different payer 
bodies, the US payer landscape will likely increasingly resemble that of Europe.
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OBJECTIVES: To identify United States (US) decision maker perceptions of data from 
observational studies and other health economics and outcomes research in the 
evaluation of emerging health technologies. METHODS: We conducted qualitative 
one-on-one interviews with payers (5), clinicians (6), and hospital administrators 
(4) in the US to determine perceptions of data collected outside of randomized con-
trolled trials in the evaluation of emerging health technologies. RESULTS: Clinical 
efficacy and safety postmarketing assessments have more of an impact on decision 
making than other types of study data collected outside clinical trials. Compared 
with other stakeholders, clinicians placed a particularly high value on patient reg-
istries, whereas, hospital administrators placed a high value on budget-impact 
analysis. Annual/semiannual review of drug classes by health plans and hospital 
formulary committees may include patient registry data; however, these data typi-
cally are not available when a new health technology is first introduced into the 
market. Real-world outcomes and head-to-head comparisons are highly desirable, 
but were also the most commonly mentioned data gaps in evaluating new health 
technologies. Clinicians more commonly sought data that affect patient treatment 
decisions, confidence in prescribing, and subpopulation data. Payers and hospital 
administrators were interested in real-world outcomes data in their specific patient 
populations, and data that could have an impact on costs, cost offsets, resource utili-
zation, and readmissions. CONCLUSIONS: Stakeholders in the US are seeking more 
